Although androgen ablation therapy is effective in treating primary prostate cancers, a significant number of patients develop incurable castration-resistant disease. Recent studies have suggested a potential synergy between vaccination and androgen ablation, yet the enhanced T cell function is transient. Using a defined tumor antigen model, UV-8101-RE, we found that concomitant castration significantly increased the frequency and function of antigen specific CD8+ T cells early after immunization of wild-type mice. However, at a late time point after immunization, effector function was reduced to the same level as non-castrated mice, and was accompanied by a concomitant amplification in CD4+CD25+FoxP3+ regulatory T cells (Tregs) following immunization.
INTRODUCTION
Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancerrelated deaths in males of the Western world (1) . Effective treatment of prostate cancer currently involves radical prostatectomy, radiation therapy and/or androgen ablation (2) . Removal of androgen leads to decreased proliferation and programmed cell death in prostate epithelial cells. Castration-resistant tumor and metastatic disease which may arise years later is largely incurable.
Immune therapy may be a promising treatment modality for castration-resistant prostate cancer (3) .
However, the role of androgen in modulating immune function, and the consequence of androgen removal/blockade on adaptive immune responses is not completely understood. Androgen is generally regarded as immunosuppressive and hormone removal increases T cell function in autoimmune disease models (4, 5) .
These observations suggest that androgen removal may augment T cell responses following immunization against prostate tumor antigens, including self proteins. However, CD8+ T cell responses to a prostate self antigen expressed in murine prostate cancer cells were only accentuated if immunization was prior to castration (6) . In contrast, the function of transgenic CD8+ T cells specific for Prostate Specific Antigen (PSA) was enhanced until 4 weeks post-castration (7) . Furthermore, in a CD4+ transgenic T cell model, a synergy between androgen deprivation and vaccination alleviated systemic tolerance to a model prostate tumor antigen, and increased T cell proliferation early after castration (8) . Thus, the ability of androgen ablation to augment immune responses to prostate tumor antigens may depend on the antigen in question, and the strength of the T cell response.
To determine the mechanism responsible for transiently increased effector function, we first investigated the effect of androgen ablation on CTL responses to a well-defined immuno-dominant tumor antigen in nontumor bearing C57BL/6 mice. The ultraviolet light-induced murine sarcoma, UV-8101-RE expresses a mutant tumor-specific protein which induces a strong CD8+ T cell response (9) . We immunized mice intra-prostatically with this antigen, and found that concomitant castration enhanced the proportion of antigen-specific CD8+ T cells in the spleen, and increased their function early after immunization which declined by 5 weeks post-4 immunization. However, we also observed an increased proportion of CD4+CD25+FoxP3+ regulatory T cells (Tregs) in the castrated and immunized animals.
We previously showed that functional CD8+ T cells responding to unknown prostate tumor antigens transiently increased following castration of prostate-specific Pten-/-mice (10) . In this study, we demonstrate that castration of Pten-/-mice also expanded Tregs. An increased frequency of functional CD8+ T cells was only detected when Tregs were depleted prior to castration and immunization with the model antigen UV-8101-RE. We further show that in vivo blockade of IL-2 prevents Treg expansion. Thus, androgen ablation amplifies both stimulatory and inhibitory arms of the immune system.
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MATERIALS AND METHODS
Animals and cell lines
C57BL/6 mice (8-12 wk old, Jackson Laboratory, Bar Harbor, ME)) were maintained under pathogen-free conditions in accordance with Institutional Animal Care and Use Committee guidelines. Prostate-specific Pten-/-mice (12-16 wk old) on the syngeneic C57BL/6 background were bred as described previously (10, 11) .
UV-8101-RE (from Dr. Hans Schreiber) and TRAMP-C1 (from Dr. Owen Witte) cell lines were cultured as described previously (10) . The authenticity of UV-8101-RE was determined by specific killing of the cell line by Į-8101-specific T cells which also recognize the mutant peptide epitope. Expression of SV40 viral DNA sequences and H-2K b were determined in TRAMP C-1 cells.
Surgery
Mice were injected i.p. with ketamine and xylazine (23.75 mg/mL ketamine + 1.25 mg/mL xylazine) (150 mg/kg). A lower midline incision was made and testes were removed. For immunization, 1x10 6 live UV-8101-RE cells in 20 Pl volume, containing bromphenyl blue for visualization were injected into both anterior and dorsal lobes of the prostate .All surgical and post-surgical care was in accordance with WFSM ACUC guidelines.
ELISpot assays
Rat anti-mouse IFNJ antibody (2.5 ȝg/ml, clone R4-6A2, BD Pharmingen, San Diego, CA) was used to coat Mixed lymphocyte tumor cell cultures (MLTC) and 51 Cr-release assays MLTC and 51 Cr release assays were conducted as described previously (9) . The percentage of specific lysis was calculated by the formula: % cytolysis = [(experimental release-spontaneous release)/(maximum releasespontaneous release)]×100.
Treg depletion
Tregs were depleted by a single i.p. injection of 0.5 mg anti-CD25 antibody (12) (clone PC61, BioXCell, West
Lebanon, NH), two days prior to castration and/or immunization.
IL-2 neutralization
To neutralize IL-2 function mice were given 1mg of anti-IL-2 mAb (clone S4B6, BioXCell, West Lebanon, NH) or isotype control i.p. two days before castration or sham-surgery, as previously described (13).
Peptide production
The mutant p68 RNA helicase peptide (SNFVFAGI) was produced by the WFSM Protein Analysis Core Laboratory essentially as described previously (9) . Briefly, the peptide was synthesized on an Applied
Biosystems (Foster City, CA) Model 430B automated peptide synthesizer, using the standard Applied Biosystems FastMoc solid phase peptide synthesis chemistry protocol. The peptide identity and purity was demonstrated by reverse phase HPLC, quantitative amino acid analysis, and MALDI-TOF mass spectrometry.
Flow cytometry analysis
Splenocytes were dissociated and stained with fluorochrome-conjugated antibodies specific for CD4 (clone RM4-5, FITC conjugated), CD8 (clone 53-6.7, FITC conjugated), CD62L (clone MEL-14, APC conjugated) from BD Pharmingen and CD44 (clone IM7, PE conjugated) and CD25 (clone PC61.5, PE conjugated) from eBioscience (San Diego, CA), all used at 1:100 dilution. Tregs were analyzed using the mouse Treg staining kit (eBioscience), and manufacturer's instructions. Cells were analyzed on a FACSCalibur™ equipped with Cellquest PRO ® software (BD Biosciences).
Tetramer production
MHC monomer was constructed and purified as described (14) , except a plasmid clone expressing H-2K b was
used. The folding, purification, and biotinylation of K b + peptide complexes were performed as described (15).
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To prepare tetramer, 20 Pl of monomer (2mg/ml) was incubated at room temperature with 1/10 volume of 128
Pl streptavidin-PE (0.5 mg/ml) (Jackson ImmunoResearch, West Grove, PA) or 95 Pl streptavidin-PerCP-Cy5.5
(0.2mg/ml) (BD Pharmingen) added in 10 minute intervals, and incubated in the dark.
Tetramer enrichment
Tetramer enrichment was performed as described previously (16) . Dissociated splenocytes stained with PE and PerCP-Cy5.5 conjugated tetramers (4ȝg/ml each) were also co-stained with CD8-FITC and CD44-APC. PEtetramer positive cells were enriched with anti-PE magnetic beads (BD Biosciences), and analyzed on a 
TGF-ȕ ELISA
Blood samples were collected from mice by cardiac puncture and the serum harvested by centrifugation. Total TGFȕ levels were determined using a commercial ELISA kit (Promega, Madison, WI).
Statistical analysis
Statistical comparisons were performed using the unpaired Student's t test with a two-sided Į level of 0.05.
Differences in values at p<0.05 were considered significant.
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RESULTS
Precursor frequency and function of CD8+ T cells responding to a model tumor antigen increased following castration and immunization of non-tumor bearing mice
Previous studies reported that castration induces infiltration of T cells into the prostate in both normal (17) and prostate tumor bearing mice (10, 17) . Using the prostate-specific Pten-/-mouse model of endogenous prostate cancer, we showed that the accumulation of functional T cells in the prostate glands is not long-lasting, evident at 2.5 weeks after castration but diminished at 5 weeks post-castration (10).
Antigens shed by dying prostate cancer cells after castration may stimulate CD8+ T cell responses. In an effort to track effector responses to an antigen located in the prostate, we utilized a defined tumor model system.
The C57BL/6-derived murine sarcoma cell line UV-8101-RE expresses an H-2K b -restricted immunodominant antigen which elicits a strong CTL response which rejects the tumor cells (9) . To model T cell interactions to prostate antigens, normal male C57BL/6 mice were immunized with UV-8101-RE cells intra-prostatically in both anterior and dorso-lateral prostate lobes, and were either castrated or sham treated. Spleens and prostate draining lymph nodes (PDLNs) were harvested 2.5 weeks later.
In order to quantify the number of UV-8101-specific responding CD8+ T cells, we produced H-2K Figure 2B ). MLTCs from mice that were castrated or sham castrated had low lytic activity ( Figure 2C ) and IFN-Ȗ production ( Figure 2D ) after ex vivo re-stimulation at 5 weeks posttreatment. Thus, increased function after castration diminished rapidly.
Castration increased splenic Tregs following immunization of non-tumor bearing mice
We investigated the mechanism for transient effector function after castration. Systemic Tregs can suppress CD8+ T cell responses to immunization (18) (19) (20) . We quantified the proportion and number of Tregs in wild-type animals following immunization, and found similar levels at 2.5 weeks following castration and immunization, compared to sham-castrated and immunized mice ( Figure 3A) . Interestingly, we detected a modest but significant increase in the percentage of Tregs 5 weeks post-castration and immunization ( Figure   3B , representative flow dot plots in Supplementary Figure S1 ). The numbers of Tregs were also increased since the spleens were larger after castration (data not shown) as previously reported (5, Treg depletion also enhanced effector responses 5 weeks after castration and immunization of wild-type mice (Supplementary Figure S3) .
Treg expansion in Pten-/-tumor bearing mice is prevented by in vivo IL-2 blockade
Two key cytokines, TGFȕ and IL-2 have been shown to play an important role in generation and expansion of Tregs. To explore the potential mechanism by which Tregs expand after castration in prostate tumor bearing mice, we measured the serum level of total TGFȕ in Pten-/-mice 2.5 weeks after castration or sham-castration. Castration did not increase the concentration of serum TGFȕ concentration compared to shamtreated animals, although the level was higher in Pten-/-mice than WT non-tumor-bearing mice (supplementary Figure S4 ).
IL-2 is the signature cytokine which expands and maintains Tregs (23, 24). Increased IL-2 levels resulting from effector CD8+ T cells responding to immunizations have been shown to also amplify Tregs (25).
Notably, we found an increased population of CD25 hi Treg cells in the PDLNs and spleens of castrated mice, suggesting that cell surface expression of CD25 was increased or a population of CD25 hi cells was preferentially expanded ( Figure 6A ). We were unable to detect IL-2 in the serum of castrated or sham-treated
Pten-/-mice (detection limit 3.1 pg/ml, data not shown).
To determine whether Treg expansion was prevented by IL-2 blockade, we administered IL-2 neutralizing antibody or isotype control two days before castration of Pten-/-mice. We analyzed the percentage and number of Tregs in the PDLNs and spleen 2.5 weeks after castration. Indeed, IL-2 neutralization significantly reduced the percentage and number of Tregs in the spleen ( Figure 6B ). The Treg proportion in the PDLNs was also decreased, but the total number remained the same since the LNs were enlarged. Finally, IL-2 neutralization reduced CD25 hi Foxp3+ cells in the spleen and PDLNs ( Figure 6C , p=0.07 for numbers in PDLNs), suggesting that Tregs expanded in response to IL-2 generated after castration.
DISCUSSION
Some studies suggest that androgen is immune suppressive and can increase the proportion of systemic Tregs, and thus dampen or ameliorate autoimmune reactions (4, 5, 26) . Other reports showed that effector cell function was increased in prostate tumors early after castration, and suggested that hormone blockade or surgical castration were immune stimulatory (17, 27) . However, immune augmentation must be short lived, since castration-resistant disease recurs in many patients.
To Expansion of Tregs by systemic IL-2 following immunization is observed in a variety of models (31) (32) (33) (34) (35) (36) (37) (38) , demonstrating a direct link between T cell activation and amplification of inhibitory mechanisms (25 Foxp3+ Tregs has been well established (39) (40) (41) . Primary prostate cancers produce TGF-ȕ (42-44) and the residual tumor remaining after castration can exert immune suppressive effects by secreting this cytokine. We detected TGF-ȕ message in the tumors early and late after castration (data not shown), and similar levels of TGF-ȕ was present in the serum of both intact and castrated Pten-/-mice. The increase in systemic Tregs after castration of Pten-/-mice was accelerated compared to wild-type mice, occurring 2.5 weeks after castration.
Tumor-produced TGF-ȕ may synergize with IL-2 generated after castration, resulting in early expansion of Tregs (45) .
In summary, we have identified a dual effect of androgen ablation on immune function, which amplified both effector and inhibitory arms of the immune system. This dual function was also implied by a recent study of human prostate cancer samples (46) . Therapeutic vaccination for treatment of castration-resistant prostate cancers has a small window of opportunity following androgen ablation which may be widened by the addition of Treg depletion to the regimen.
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